This blog highlights research and development of new treatments, outcomes of global clinical trials and their regulations, with a special focus on ophthalmology and retinal diseases, including drugs and devices. The blog is meant for both clinical and pharmaceutical experts, as well as for patients / family members who are looking for information.
A significant number of people, both in clinics and in pharmaceutical industry, mention the fact that they keep hearing of the word 'biosimilars' in academic meetings and in discussions, but they have no idea what they are, and what they do. Considering that biosimilars are likely to affect the way we practice medicine in the days ahead, it is important that we are aware of what biosimilars mean, and what they do. Also, it is important from the pharmaceutical industry perspective that everyone is knowledgeable of the process for an approval. Lastly, there is a minuscule, but very relevant question, about legal implications, which may or may not break your/your company's back in getting the drug to the market! The last two topics will be covered in subsequent posts.
